The CDNR Platform – Progressing the Promise of Personalized Medicine

April 9, 2018 | Posted by Team in Innovation Highlight |

by Gursatya “Guru” Singh, Director of Scientific Content, Science Exchange

Most everyone knows that precision medicine promises to transform the healthcare landscape, delivering powerful and personalized treatments for previously intractable diseases. Even so, biotech innovators still face tremendous hurdles in realizing this promise — chief among them, finding access to sufficient numbers of annotated, characterized and consented patient samples.

Novaseek Research has developed a unique solution to this dilemma: the Clinical Data Network for Research platform — otherwise known as CDNR.

CDNR Novaseek Research Science Exchange

CDNR provides instant access to thousands of ethically-sourced patients’ specimens and associated real-world clinical data in pursuit of advancing the field of personalized medicine. Novaseek obtains biosamples and associated data through its extensive network of physicians, clinical labs, and hospitals. Within this network, Novaseek actively recruits patients to match targeted research needs. Novaseek also maintains a large searchable database of de-identified clinical information representing millions of patients.

Through the Novaseek platform, researchers can easily obtain the data they need throughout the product life cycle. For instance, researchers seeking the statistics necessary for in vitro diagnostics submissions can gain access to sufficient numbers of annotated, characterized and consented patient samples and related data. With CDNR, obtaining clinical data and biospecimens is seamlessly integrated into R&D.

Learn more about Novaseek Research on their Science Exchange storefront.

 

Take 5 – The Future of Now — How the Science of Today Shapes Tomorrow

March 21, 2018 | Posted by Team in Innovation Highlight |

by Gursatya “Guru” Singh, Director of Scientific Content, Science Exchange

Scientific research is advancing without pause; innovations are emerging at a breathtaking rate all over the world through the endeavors of diverse scientific disciplines. The future of scientific research is set on an unpredictable course teeming with both excitement and unease — whether AI-enabled tools will reshape drug discovery or if “patient-on-a-chip” technology will let future scientists create custom therapies for patients on the spot remains to be seen. Amidst the uncertainty, one thing remains clear: Science Exchange will be your fastest path to accessing new and emerging research tools, technologies, and services as the future continues to unfold.

A moment’s time is all you need to learn about the benefits of five promising technologies that may play an integral role in the near future. Sit back and Take 5! If something grabs your interest, click on the provided link to learn more about each service.

 

NanoMIPS

NanoMIPS

These novel affinity reagents, sometimes called “plastic antibodies,” have similar specificity to antibodies and can replace antibodies in in vitro applications, including sensing, imaging, purification, analysis, and diagnostics.

NanoMIPs are nanostructured Molecularly Imprinted Polymers, which typically contain a single binding site to a template molecule. NanoMIPs are prepared via a proprietary imprinting process that involves the self-assembly of binding monomers around a target template—these monomers are then polymerized to generate a “synthetic receptor” with high affinity and specificity to the template.

LEARN MORE

 

 

FANA Antisense Oligonucleotide (FANA – ASO) TechnologyFANA Antisense Oligonucleotide (FANA – ASO) Technology

This next-generation chemical modification platform provides a superior alternative to CRISPR, siRNA, and shRNA approaches, and can be used to silence or regulate different RNA modalities.

Unlike conventional technologies, FANAs have high fidelity for the RNA target and highly reduced off-target effects (no RISC-associated off-target effects). These attributes represent a more potent, efficient, and cost-effective solution for RNA silencing and regulation.

LEARN MORE

 

 

Intestinal Microbiota ScreeningI-SCREEN – Intestinal Microbiota Screening Platform

This translational intestinal screening multi-well platform simulates the human colonic microbiota conditions in vitro and helps identify the pharmacological compounds metabolized by intestinal microbiota.

The Netherlands Organization (TNO)’s i-screen service enables rapid identification of drugs that are susceptible to metabolism by intestinal microbiota. Additionally, it can be used to identify unknown metabolites transformed by intestinal microbiota.

LEARN MORE

 

 

DigiWest™ Multiplex Protein ProfilingDigiWest™ Multiplex Protein Profiling Services

This service enables comprehensive profiling of up to 800 total and phosphoproteins from cell and tissue samples, using just 20–60 μg of protein.

Unlike other protein-profiling technologies, DigiWest allows in-depth analyses of cell signaling pathways on the level of phosphorylated proteins. As such, DigiWest adds significant value to biomarker identification, precision medicine, compound characterization, and mode-of-action studies.

LEARN MORE

 

 

Visikol 3DScreen3DScreen™ High-Content Assay Development

This unique service is based on a patent-pending biological clearing agent called Visikol™ that penetrates tissue and renders it transparent without causing structural damage.

The assay has applications in the fields of toxicology, preclinical drug development, clinical diagnostics, basic research and plant biology, as tissues can be easily visualized in 3 dimensions.

LEARN MORE

 

 

Request quotes for these innovative services today!

request quotes button

On-demand Webinar: Informatics for Biologists

March 5, 2018 | Posted by Team in Webinar |

Put Your Genomics Data to Work — No Bioinformatics Skills Needed

Are complex data analyses delaying YOUR valuable and critical results from being put to action?

Watch this on-demand webinar to learn how the Rosalind™ platform empowers you to analyze your own data, more quickly and cost-effectively — even for the most complex studies.

You’ll hear from bioinformatics expert, Jean Lozach, Chief Technology Officer, and Karl Yoder, Product/Business Development, at OnRamp Bioinformatics.

You will learn about:

  • The fastest path to interactive genomic analysis, RNA-seq gene expression, single-cell expression, CRISPR and many other complex analyses
  • How the Rosalind™ platform and the OnRamp Bio scientific team can help biologists and other researchers can look deeper into their own data without any bioinformatics skills

About Our Speakers

Jean Lozach OnRamp Bio

Jean Lozach joined OnRamp Bio after more than 25 years experience in Genomics, Bioinformatics and Information Technology at Illumina and UCSD. As Associate Director of Enterprise Informatics over the last 5 years, Jean set up and drove customer success for Illumina’s BaseSpace solution for bioinformatics. He uniquely brings deep experience and knowledge of biology, wet lab operations, microarrays, and NGS together with advanced bioinformatics, software development and enterprise IT infrastructure. Jean is an industry expert in genomics and bioinformatics and has led dozens of successful core facility deployments of NGS and informatics systems.

Karl Yoder OnRamp BioinformaticsKarl Yoder is a member of the product development and business development teams at OnRamp Bioinformatics. He joins the company after more recently helping to grow a successful biotech focused on therapies involving the human gut microbiome. He earned his MA from UC San Diego and BA from Princeton.

 

Have genomics data you need to interpret?

Request a free quote from the OnRamp Bioinformatics team!

request quotes button

Likarda Chooses Science Exchange as the Primary Online Channel to Offer 3D Compound Screening and Assay Development Services to Scientists

February 28, 2018 | Posted by Team in News |

Likarda Partners With Science Exchange

PALO ALTO, CA, February 28, 2018 – Science Exchange, the world’s leading platform for outsourced research and development (R&D) services, announced a partnership with Likarda to offer online access to its innovative 3D compound screening and assay development services to scientists around the globe.

Likarda is a Kansas City-based contract research organization (CRO) and a leading provider of drug discovery and development services, primarily using 3D cell-based assaying technologies and microencapsulation. The company’s mission is to combine comprehensive early-phase discovery research with consultative and analytical services so that those in the drug discovery process can move forward confidently, efficiently, and affordably.

“We focus on bringing to market disruptive technologies that improve healthcare outcomes and lower costs for pets and people alike. To illustrate, our proprietary three-dimensional cell culture system serves as a predictive model to demonstrate how test drug compounds work in the human body. Partnering with Science Exchange gives its global client base the fastest path to our novel technologies and services,” stated Karthik Ramachandran, Ph.D., Likarda’s vice president and co-founder.

“We are excited to team up with Likarda to make its drug screening and assay development services accessible to scientists worldwide,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange.  “Science Exchange is committed to adding the most innovative and qualified service providers to our platform, so scientists can securely and readily access the services they need to aid their discoveries.  Likarda met our rigorous standards for quality and compliance while demonstrating breakthrough discoveries in the field of 3D cell-based assaying technologies and microencapsulation.”

About Likarda

Founded in 2012, Likarda LLC is a world-class, cutting-edge biotech research laboratory for science entrepreneurs, pharmaceutical and nutraceutical companies, animal health, and contract research organizations (CRO). We focus on bringing to market disruptive technologies that improve health-care outcomes and lower costs for pets and people alike. Follow the CRO on Twitter @likardallc.

 

Interested in trying out Likarda’s technologies for your project?

Request a quote from the Likarda team

Tech Q&A with CARE Research

February 12, 2018 | Posted by Team in Provider Spotlight |


 

Chandreyee Das, PhD, of Science Exchange recently spoke with Rajan Bawa, PhD, of CARE Research LLC, a leading preclinical CRO combining quality service for clients with excellent quality of life for animals — even for challenging or complex projects.

CD: Rajan, you’ve been in the pharmaceutical and biotechnology industry for over 40 years, can you tell us your company’s story?

RB: Twenty years ago, I started this histopathology company, Colorado Histo-Prep. In 2010, we acquired one of our preclinical CRO clients, which was CARE Research, enabling us to provide a one-stop-shop for our clients in the preclinical space.

CD: What capabilities does CARE Research have that set the company apart from other preclinical CROs?

RB: One differentiator is our ability to start projects very swiftly, with quick IACUC approval. We have extensive technical and regulatory experience.

Also, our responsiveness to our sponsor needs, being proactive in providing ongoing progress reports — we don’t wait until things go wrong.

We’re relatively small — we have about 20 people — but that means that we have high-ranking people in our organization — say, VP of Toxicology, or IACUC chairs — actively involved in projects. In large preclinical CROs, very often, there’s a study director who sits in his office, doesn’t even make it to the lab until the sponsor comes to visit.

CD: What preclinical services do you offer that are differentiated from other service providers?

RB: One area of strength is in DART (Developmental and reproductive toxicology) studies and ocular studies. DART services are not often offered by small or medium CROs, because they lack the expertise to carry out these specialized studies.

Ocular studies are another of our core competencies — these are also complex studies, you really have to know what you’re doing.

CD: What type of certifications does CARE Research hold?

RB: That’s a great question. We are OLA certified, AAALAC accredited, and we are GLP. We’re inspected regularly by FDA and USDA.

CD: What types of clients do you serve?

RB: We have a mix of different sponsors. We have large pharma, small biomedical companies, university researchers, startup companies.

In addition to our flexibility and ability to respond quickly, we have the ability to do very complex projects, especially in the surgical and ocular area in contrast to other CROs who may stay away from complex studies.

CD: Finally, could you describe your experience with Science Exchange?

RB: Science Exchange allows us to widen our reach, and allows us to find clients we would not have found using our internal resources. Also, the project managers whom I’ve interacted with are very helpful and responsive, and easily available to answer any questions, provide clarifications, etc in a patient manner.

 

Request a quote from CARE Research and get on the fastest path to completing your preclinical studies.

request quotes button

 

Science Exchange Announces Outsourced R&D Collaboration with UC Davis Venture Catalyst Group

February 12, 2018 | Posted by Team in News |

Science Exchange Venture Catalyst Collaboration

Palo Alto, CA – February 12, 2018 — Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development (R&D), today announced a strategic collaboration with Venture Catalyst, a unit within the Technology Management and Corporate Relations division of the UC Davis Office of Research which supports the development of new ventures fueled by university research.

Science Exchange will provide entrepreneurs and startups participating in the Venture Catalyst Smart Toolkit for Accelerated Research Translation (START™) Program immediate access to the private R&D marketplace with dedicated PhD-level sourcing support around the clock and a special contracting structure to accelerate their research and development projects.

“The Science Exchange platform solves the challenges of R&D outsourcing by providing scientists with on-demand access to a diverse network of prequalified external providers under a single relationship while also providing sourcing departments with more information and control over their outsourcing spending,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “We are thrilled to be collaborating with Venture Catalyst to offer a customized R&D marketplace and help its portfolio of companies complete their research and clinical projects more quickly and efficiently. It’s clear that Venture Catalyst is supporting companies with extremely promising technologies in development, and we’re honored to help get their discoveries to market faster.”

With this collaboration, Science Exchange will support client-specific governance, approval workflows, and preferred vendors, all the while enabling instant access to research services and custom products from 2,500 providers in over 6,000 research areas. To help external service providers minimize the risk frequently associated with outsourcing,  Science Exchange’s guarantee ensures complete protection of data, assets and performance of agreed-upon services, all backed by the best-in-class, SOC 2-compliant information technology security infrastructure. Science Exchange’s ISO 9001-certified quality assurance system and dedicated regulatory compliance team also support regulated outsourced work.

Venture Catalyst is the latest innovation and startup support organization to choose to partner with Science Exchange. They now join more than 30 enterprise organizations including most of the top 20 biopharma companies that use Science Exchange to more efficiently manage outsourced R&D.

“Science Exchange offers a unique platform for our startups to connect with a broad network of qualified scientific providers,” said Dushyant Pathak, Associate Vice Chancellor of Research and Executive Director of Venture Catalyst at UC Davis. “We anticipate that working with Science Exchange through the START Program will enable us to commercially advance the discoveries made by Venture Catalyst-supported startups and early-stage companies, in areas as diverse as biomedical and life sciences, agriculture and animal health, and physical sciences and engineering.”

 

About Venture Catalyst

Venture Catalyst furthers the University’s educational, research and public mission by supporting UC Davis students, faculty and researchers in translating science, engineering and innovative research through well-resourced startups, into societal impact.  Venture Catalyst engages collaboratively with internal and external drivers of innovation and works closely with the University’s Institute for Innovation & Entrepreneurship.  In addition to its Smart Toolkit for Accelerated Research Translation (START™) program, Science Translation and Innovative Research (STAIR™) Proof-of-Concept grants, Venture Catalyst supports a network of regional technology startup incubators through its Distributed Research Incubation & Venture Engine (DRIVE™) Network.

Rapid Novor Inc. Launches REmAb™ Antibody Protein Sequencing Services on Science Exchange

January 24, 2018 | Posted by Team in News |

PALO ALTO, CA, January 25, 2018 – Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development (R&D) services, announced a partnership with Rapid Novor Inc to offer its REmAb™ Antibody Protein Sequencing Services to scientists around the world using Science Exchange’s R&D platform.

Rapid Novor, Inc. is a Kitchener-Waterloo (Canada)-based CRO dedicated to the development of antibody protein sequencing technologies. The company’s mission is to advance life science research to better human health with next-generation protein sequencing. With the opening of its own state-of-the-art mass spectrometry lab in 2017, the team has successfully sequenced hundreds of monoclonal antibodies directly from the proteins and helped pharmaceutical companies in their antibody drug discovery.

“Our focus is on the development of antibody protein sequencing technologies, and we are the only team that has both a mass spectrometry lab and proprietary sequencing software platform,” said Mingjie Xie, Co-founder and CEO of Rapid Novor, Inc. “We are uniquely positioned to offer superior protein sequencing services to researchers worldwide. The partnership with Science Exchange will allow us to provide easy-to-access services to enterprise biopharma companies and offer them cutting-edge technologies in a seamless manner.”

“We are thrilled to partner with Rapid Novor Inc to make its REmAb™ Antibody Protein Sequencing Services available to scientists worldwide,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “By partnering with the leading CROs in different research and technology sectors, we are bringing in the best and brightest service providers to our secure and readily available platform so that the scientists can focus on developing breakthrough discoveries. Having Rapid Novor Inc as part of our supplier portfolios is an example of our commitment to making it easy for researchers to access the world’s leading scientific service providers and most innovative scientific technologies.”

About Rapid Novor, Inc.

Rapid Novor, Inc. is the world’s leader in antibody protein sequencing technology. Specializing in the field of mass spectrometry-based proteomics, the team has developed the technology to directly sequence the antibody proteins without needs to access the cell line. As a University of Waterloo spin-off, the company is building its technology portfolios based on the twenty years of scientific research and inventions from Dr. Bin Ma, co-founder and chief scientist. The company’s REmAb™ antibody protein sequencing service has allowed the accurate sequencing of any given antibody proteins routinely. The company’s WILD™ service is the first commercially available service that can accurately distinguish the isomeric isoleucine and leucine using mass spectrometry. For more information, visit www.rapidnovor.com. Follow the company on Twitter @rapidnovor.

Science Exchange Partners with Lab Launch to Help its Startups Advance Scientific Innovations

January 10, 2018 | Posted by Team in News |

Lab Launch Science Exchange Enterprise Outsourcing PlatformPalo Alto, CA – January 10, 2018 — Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development (R&D), teamed up today with Lab Launch, a nonprofit working to provide affordable and high-quality laboratories to biotech startups. This partnership with Science Exchange allows Lab Launch’s resident companies to easily supplement and complement their in-house resources with external research tools, technologies, and expertise.

Science Exchange enables immediate access to over 2,500+ commercial CROs, academic labs, and government facilities under a single marketplace agreement, in addition to a 24/7 PhD-level support by Science Exchange staff scientists.

“Our goal is to give LA-based scientists and entrepreneurs every opportunity to further their ideas and innovations in a way that is affordable and that will also give them access to the best scientific resources available,” said Marie Rippen, CEO of Lab Launch.  “By partnering with Science Exchange, Lab Launch can now offer our companies access to fully vetted service providers in a secure environment, so our scientists can devote time to advancing their ideas instead of being bogged down with administrative tasks including researching and negotiating with service providers.”

“Lab Launch and Science Exchange are both driven to give scientists the tools and support they need to be successful in developing their breakthrough ideas,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “Scientists at Lab Launch will now automatically gain access to the best scientific providers to help bring groundbreaking discoveries to market. We are excited to be part of the process!”

Lab Launch is the latest R&D organization to choose to partner with Science Exchange and joins more than 30 enterprise clients and Life Science incubators that are effectively managing their outsourced R&D with Science Exchange-powered marketplaces.

About Lab Launch

Lab Launch Inc is a 501(c)(3) non-profit working to establish a more dynamic biotech startup environment in Los Angeles. Our mission is to enable LA’s scientists and entrepreneurs to develop their ideas in affordable, high-quality lab facilities, with access to services and a supportive innovation community to accelerate their success.

 

Request a demo of Science Exchange’s platform to see how your organization can benefit from increased access to innovation and organizational efficiency.

Innovation Drives Operational Challenges that Impact R&D Productivity

December 21, 2017 | Posted by Team in Outsourcing Trends |

by Elizabeth Iorns, Ph.D., CEO and Co-Founder, Science Exchange
Originally appeared in the 2017 Fierce Life Science Innovation Report (download PDF)

Fierce LS Innovation Report

R&D productivity and efficiency are key measures for evaluating the success of biotech and pharma companies. In theory, investing resources into R&D to boost those measures should yield positive results. Unfortunately, recent trends suggest a less desirable outcome.

A primary driver of the R&D productivity decline is the prolific growth in innovative therapeutic modalities. The first siRNA therapeutics, CAR-T engineered cells, and viral gene therapies have all been approved by the FDA within the past 2 years alone.  This innovation in the biotech and pharma industry has enabled spectacular successes in the treatment of devastating diseases, but it comes with significant operational challenges.

In contrast to the well-known development process for small molecules, these new highly specialized therapeutics require exponentially more diverse and complex technologies and expertise.  So how do biotech and pharma companies access this evolving set of technology and expertise?  Increasingly, they have shifted to a reliance on an external R&D ecosystem.  By outsourcing, companies can manage fixed costs while accessing specialized technologies, particularly in complex R&D areas. As of 2017, nearly half of R&D budgets are spent on outsourced scientific services and the trend is increasing.

But, several challenges prevent companies from realizing returns on their outsourcing investments.

  • First: even though outsourcing represents a rapid path to new technologies, identifying relevant and qualified service providers is a time-consuming task that can take weeks or even months.
  • Second: contracts required to maintain confidentiality, protect IP, and ensure compliance can delay project initiation and add to transaction costs.
  • Third: R&D organizations may have thousands of individual scientists conducting tens of thousands of outsourced R&D projects each year. Maintaining visibility, monitoring performance, measuring success represent a significant management burden.

Science Exchange directly addresses these challenges and has demonstrated a significant impact on productivity and efficiency in R&D programs around the world.  The Science Exchange platform uniquely provides a marketplace of pre-qualified and pre-contracted outsourced R&D service providers to provide scientists with instant access to the innovative services necessary to advance today’s pipeline.  

Get help leading change at your organization: request a demo of the Science Exchange  platform.

Breakout Labs Partners with Science Exchange to Empower its Portfolio Companies with External Research Innovations

December 18, 2017 | Posted by Team in News |

Breakout Labs Science Exchange

Palo Alto, CA – December 18, 2017 — Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development (R&D), today announced a strategic partnership with Breakout Labs, a fund within the Thiel Foundation that backs scientist-entrepreneurs working at the intersections of technology, biology, materials, and energy. The newly formed partnership allows for Breakout Labs to provide its portfolio companies’ scientists with on-demand access to a global network of research suppliers via the Science Exchange-powered private marketplace.

The private marketplace enables instant access to thousands of research tools, technologies, and services from over 2,500+ commercial CROs, academic labs, and government facilities under a single Science Exchange contract. Additionally, the platform users receive end-to-end PhD-level support from the Science Exchange staff scientists in identifying the best external innovations to expedite their R&D cycles.

“Our companies are small innovative startups that, despite being cash-constrained, are at the forefront of radical scientific breakthroughs,” said Hemai Parthasarathy, Scientific Director of Breakout Labs.  “Science Exchange’s marketplace helps these companies adopt virtualization in their R&D process and give them an opportunity to access external resources they need to bring their innovations to market. Science Exchange fits into the ethos that prompted the formation of Breakout Labs by removing barriers for startups to access scientific services that will help accelerate their discoveries.”

“At Science Exchange, we are passionate about accelerating discovery by making connections — in this case, vital connections between scientist-entrepreneurs and experienced providers of scientific products and services,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “Through this partnership, the scientists at Breakout Labs’ companies, can now focus on what they do best, bringing game-changing scientific discoveries to market, and rely on us to find the best scientific providers to help them accomplish that.”

Breakout Labs is the latest R&D organization to choose to partner with Science Exchange and join more than 30 enterprise clients and Life Science incubators that are effectively managing their outsourced R&D with Science Exchange-powered marketplaces.

About Breakout Labs

Breakout Labs is a revolving fund within the Thiel Foundation that supports early stage companies as they transition radical scientific advances out of the research lab and into the economy. The program backs bold scientists who work at the intersections of technology, biology, materials, and energy. More than capital, Breakout Labs provides additional support through a two-year program that includes introductions to follow-on funders, corporate partners and other resources to drive commercialization. To learn more, visit: www.breakoutlabs.org.

About Science Exchange

We are transforming scientific collaboration by creating a marketplace where scientists can order experiments from the world's top labs.

Check the Science Exchange blog for updates, opinions, guest posts and the latest happenings at Science Exchange HQ!

Visit Science Exchange →

Subscribe to the blog
Never miss a post! Science Exchange blog posts delivered right to your inbox.
Thank you for joining the SciEx revolution!
Powered By WPFruits.com